Valproic acid treatment is associated with altered leukocyte subset development

Research output: Contribution to journalArticleAcademicpeer-review


Valproic acid (VPA) has been used for decades in the treatment of epilepsy and psychiatric disorders, and the long-term use of VPA is regularly accompanied by hematological toxicity, including neutropenia. More recently, it has been demonstrated that VPA can be used as a histone deacetylase inhibitor (HDACi) for the treatment of hematological malignancies. In order to determine the specific effects of VPA in both hematological malignancies and normal hematopoiesis, recent studies have demonstrated that VPA treatment affects the differentiation of normal myeloid progenitors in vitro. In this study, we demonstrate that in a large patient population treated for neurological or psychiatric disorders, VPA treatment affects neutrophil as well as lymphocyte subset counts.

Original languageEnglish
Pages (from-to)832-834
Number of pages3
JournalJournal of Clinical Psychopharmacology
Issue number6
Publication statusPublished - Dec 2012


  • Eosinophils/drug effects
  • Hematopoiesis/drug effects
  • Humans
  • Leukocyte Count/methods
  • Leukocytes/cytology
  • Lymphocyte Subsets/drug effects
  • Mental Disorders/blood
  • Monocytes/drug effects
  • Neutrophils/drug effects
  • Treatment Outcome
  • Valproic Acid/adverse effects


Dive into the research topics of 'Valproic acid treatment is associated with altered leukocyte subset development'. Together they form a unique fingerprint.

Cite this